Biosplice Therapeutics

aid: biosplice-therapeutics
name: Biosplice Therapeutics
description: 'Biosplice Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in
  San Diego, California, founded in 2008 by Osman Kibar and known until its 2020 rename as Samumed, LLC (samumed.com still
  redirects to biosplice.com). The company develops first-in-class small-molecule therapeutics that act on novel components
  of the Wnt signaling pathway and on the regulation of alternative pre-mRNA splicing. Its lead program is lorecivivint, an
  investigational intra-articular knee injection for osteoarthritis, positioned against a stated unmet need of "over 50 million
  US patients suffer from osteoarthritis, with no drugs available to arrest the disease"; the candidate has completed Phase
  3 study and a New Drug Application has been submitted to the U.S. Food and Drug Administration. Programs outside lorecivivint
  — neurology, diabetes and oncology — are developed by the company''s affiliate TenaRx, Inc. The company is led by Erich
  Horsley (Chief Executive Officer) with Osman Kibar as Founder and Executive Chairman, Yusuf Yazici as Chief Medical Officer,
  Phil Wilson as Chief Financial Officer and Scott W. Bulcao as Chief Legal Officer. Biosplice is a drug-discovery and clinical-development
  organization, not a software vendor: biosplice.com is a small ASP.NET corporate site covering mission, board, management,
  advisors, programs, publications, news and careers, and the company publishes no developer program of any kind — no API,
  no SDK, no developer portal, no GitHub organization and no machine-readable API contract.'
url: https://raw.githubusercontent.com/api-evangelist/biosplice-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
specificationVersion: '0.23'
created: '2026-08-07'
modified: '2026-08-07'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Development
- Clinical Trials
- Osteoarthritis
- Small Molecule Therapeutics
- Healthcare
- San Diego
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Development
- Clinical Trials
- Osteoarthritis
- Small Molecule Therapeutics
- Health Care
- San Diego
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/biosplice-therapeutics-domain-security.yml
- type: WellKnown
  url: well-known/biosplice-therapeutics-well-known.yml
- type: LLMsTxt
  url: llms/biosplice-therapeutics-llms.txt
- type: Website
  url: https://www.biosplice.com/
- type: About
  url: https://www.biosplice.com/mission/default.aspx
- type: Pipeline
  url: https://www.biosplice.com/our-programs/detail.aspx?id=20
- type: Team
  url: https://www.biosplice.com/management/default.aspx
- type: Publications
  url: https://www.biosplice.com/publications/default.aspx
- type: News
  url: https://www.biosplice.com/news/default.aspx
- type: Blog
  url: https://www.biosplice.com/news/default.aspx
- type: Careers
  url: https://www.biosplice.com/careers/default.aspx
- type: Contact
  url: https://www.biosplice.com/contact-us/default.aspx
- type: Support
  url: https://www.biosplice.com/contact-us/default.aspx
- type: PrivacyPolicy
  url: https://www.biosplice.com/privacy/default.aspx
- type: TermsOfService
  url: https://www.biosplice.com/terms/default.aspx
- type: LinkedIn
  url: https://www.linkedin.com/company/biospliceinc
- type: SecondaryMarket
  url: https://forgeglobal.com/biosplice-therapeutics_stock/
x-enrichment:
  date: '2026-08-07'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Biosplice is a clinical-stage drug developer whose product is an injectable small molecule, not software; www.biosplice.com
    is a 13KB ASP.NET brochure site with no robots.txt and no sitemap.xml, every spec and /.well-known/ path is rewritten
    to the CMS 404 page, and api./developer./docs./portal./status./graphql./mcp.biosplice.com have no DNS record at all.
  evidence:
  - url: https://www.biosplice.com/openapi.json
    status: 404
  - url: https://www.biosplice.com/.well-known/agent-card.json
    status: 404
  - url: https://www.biosplice.com/.well-known/agent.json
    status: 404
  - url: https://www.biosplice.com/llms.txt
    status: 404
  - url: https://www.biosplice.com/sitemap.xml
    status: 404
  - url: https://api.github.com/orgs/biosplice
    status: 404
  checked: '2026-08-07'